Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to trace Akero Therapeutics鈥� cash runway or pinpoint when Phase 3 EFX data will hit? Biotech disclosures are dense, and Akero Therapeutics SEC filings explained simply can save hours of scrolling. Our platform tackles the 200-page 10-K so you don鈥檛 have to, flagging R&D spend, trial timelines, and risk factors that matter to metabolic-disease investors.
Stock Titan鈥檚 AI reads every Akero Therapeutics annual report 10-K simplified, each Akero Therapeutics quarterly earnings report 10-Q filing, and every sudden Akero Therapeutics 8-K material events explained鈥攖hen turns legal language into plain-English insights. Want real-time alerts? The moment Akero Therapeutics Form 4 insider transactions real-time post to EDGAR, you鈥檒l see executive buys and sells, helping you monitor Akero Therapeutics insider trading Form 4 transactions ahead of critical data releases.
Here鈥檚 what you鈥檒l uncover:
- Pipeline clarity: 10-Q sections detailing EFX enrollment progress and FDA feedback.
- Capital health: Cash burn metrics and shelf registrations folded into our Akero Therapeutics earnings report filing analysis.
- Governance insight: The latest Akero Therapeutics proxy statement executive compensation shows incentives tied to NASH milestones.
- Event tracking: AI flags wording changes in new 8-Ks so you understand shifts fast.
- Ownership moves: Instant updates on Akero Therapeutics executive stock transactions Form 4.
Stop piecing together PDFs. With understanding Akero Therapeutics SEC documents with AI, you get clear analysis, real-time feeds, and the context you need to act confidently.
Akero Therapeutics, Inc. (AKRO) Form 4 filing: Chief Technology Officer Scott A. Gangloff disclosed an automatic sale of 848 shares of common stock on 18 June 2025 at a weighted-average price of $54.84 per share. The transaction was executed under the company’s mandatory “sell-to-cover” policy to satisfy tax-withholding obligations triggered by the vesting of restricted stock units, meaning it was not a discretionary trade. After the sale, the executive continues to hold 23,452 shares directly.
Akero Therapeutics, Inc. (AKRO) filed a Form 4 reporting that Senior Vice President, Commercial Strategy Patrick Lamy sold 875 common shares on 06/20/2025 at $54.59 per share. The sale was made under the company鈥檚 automatic 鈥渟ell-to-cover鈥� policy to satisfy tax-withholding obligations that arose when restricted stock units vested, and therefore was not discretionary. After the transaction, Lamy continues to own 31,698 shares directly. No derivative securities were involved, and no other insider transactions were disclosed.
Akero Therapeutics Chief Scientific Officer Timothy Rolph executed a non-discretionary sale of 1,129 shares of common stock on June 18, 2025 at a weighted average price of $54.84 per share.
Key details of the transaction:
- The sale was conducted under a "sell-to-cover" policy to satisfy tax withholding obligations related to vesting restricted stock units
- Transaction prices ranged from $54.33 to $54.84 per share
- Following the transaction, Rolph directly owns 166,234 shares
- The sale was automatic and not at the discretion of the reporting person
This Form 4 filing indicates a routine insider transaction for tax purposes rather than a discretionary sale, suggesting no significant change in the insider's investment outlook.
Insider Trading Activity Report: William Richard White, Chief Financial Officer of Akero Therapeutics (NASDAQ: AKRO), reported a sale of 1,634 shares on June 18, 2025, at a weighted average price of $54.84 per share.
This transaction was executed as part of a "sell-to-cover" arrangement to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). The sales were automatic and not discretionary, conducted at prices ranging from $54.33 to $54.84 per share.
Following the transaction, White retains beneficial ownership of 57,521 shares held directly. The sale represents a routine tax-related transaction rather than a strategic investment decision by the insider.
Akero Therapeutics, Inc. (AKRO) 鈥� Form 4 insider transaction
Chief Development Officer Catriona Yale reported a single non-derivative transaction on 18 June 2025. The filing shows the automatic sale of 1,633 common shares at a weighted-average price of $54.84 (individual trades ranged from $54.33 to $54.84). The transaction was coded 鈥淪鈥� and was executed under the company鈥檚 sell-to-cover policy to satisfy tax-withholding obligations arising from the vesting of restricted stock units. According to the footnotes, the sales were automatic and not at the officer鈥檚 discretion.
Following the transaction Ms. Yale continues to own 90,598 common shares directly. No derivative security activity was reported in Table II, and no additional transactions were disclosed.
The filing is a routine Section 16 disclosure; no earnings data, options exercises, or new awards were included.
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), reported insider trading activity on June 18, 2025. The transaction involved the sale of 1,453 shares at a weighted average price of $54.84 per share as part of a "sell-to-cover" arrangement to satisfy tax withholding obligations related to vesting restricted stock units.
Following the transaction, Young directly owns 196,594 shares and indirectly holds beneficial ownership of additional shares through three irrevocable trusts:
- 20,000 shares in EA Irrevocable Trust
- 20,000 shares in CM Irrevocable Trust
- 20,000 shares in JL Irrevocable Trust
The trusts are managed by Young's spouse for their children's benefit, with Young disclaiming beneficial ownership of these trust-held securities. The reported sale was automatic and executed according to the company's tax withholding policy, not at Young's discretion.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
